RPRX Royalty Pharma plc Class A Ordinary Shares PHARMACEUTICAL PREPARATIONS Best Pharmaceutical Stocks 2026 →

RPRX Stock Analysis: Buy, Sell, or Hold?

$70.01
+0.56 (+0.81%) ▲
5d: +3.63% 30d: +23.76% 90d: +19.55%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (27%)
Quality Score
36/100
Position
EXTENDED
30-Day Fair Range
$58.41 – $67.36
Position: EXTENDED
Forward P/E & Valuation
11.8x STRETCHED
vs 9.4x historical avg
Wall Street Target
$72.00
+2.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$64.84 / $70.27
Trend: Strong Uptrend
💡Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: RPRX shows conflicting indicators. Wait for confirmation before entering.

Get Alerted When RPRX Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$77.14
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$47.90
Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.4x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: RPRX is currently trading at $70.01, which is considered extended relative to its 30-day fair value range of $58.41 to $67.36. From a valuation perspective, the stock is trading at a premium (Forward PE: 11.8) compared to its historical average (9.4). At these levels, the market is pricing in 8.1% annual earnings growth.

Technical Outlook: Technically, RPRX is in a strong uptrend. The price is approaching resistance at $70.27. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: RPRX scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED
Historical Trading Range $58.41 - $67.36
Company Quality Score 36/100 (SELL)
Volume Confirmation HIGH
Confidence Score 27.1%

Trading Range & Key Levels

30-Day Trading Range $58.41 - $67.36
Current vs Trading Range EXTENDED
Support Level $64.84
Resistance Level $70.27
Current Trend Strong Uptrend
Technical data as of Nov 11, 2026

Protect Your Profits

RPRX is technically overbought (RSI 79). Consider hedging now to protect against a potential pullback while keeping your upside.

View Profit Protection Plan

Quantitative Signal Breakdown

  • BEARISH: Price extended above range
  • BEARISH: Weak technical setup (5/100)
  • BULLISH: High volume confirmation
  • NEUTRAL: Near Wall St target ($72.00)
  • BULLISH: Expecting earnings turnaround to 8.1% growth with 13.3% revenue growth
  • WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market

Fundamental Context

Forward P/E (Next Year Est.) 11.84
Wall Street Target $72.00 (+2.8%)
Revenue Growth (YoY) 13.3%
Earnings Growth (YoY) -50.8%
Profit Margin 25.7%
Valuation Premium vs History +8.1% premium
PE vs Historical 11.8 vs 9.4 STRETCHED
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +8.1% (market-implied from PE analysis)
1-Year Target $75.68 (+8%)
2-Year Target $81.81 (+17%)
3-Year Target $88.44 (+26%)
3-Yr Target (if PE normalizes) (PE: 12→9) PE COMPRESSION $70.19 (+0%)
Earnings growth offset by PE compression
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 19.9, Growth: 9.6%) $154.61 (+121%)
Base: (SPY PE: 11.8, Growth: 9.6%) $92.20 (+32%)
Bear: (PE: 9.4, Growth: 9.6%) $73.18 (+5%)
📈 Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (45x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 45.39 | Current EPS (TTM): $1.53
Bull Case $152.79 (+118%)
Analyst growth 100.0%, PE expands to 49.9
Base Case $138.90 (+98%)
Market implied 100.0%, PE stable at 45.4
Bear Case $47.23 (-33%)
Severe decline -20.0%, PE contracts to 38.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share RPRX Analysis

Share this live RPRX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.

Reddit StockTwits X / Twitter
bloggers & journalists: you are free to use our charts with attribution.

Reddit & Retail Trader Sentiment (RPRX)

Bullish 2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
May 24, 2026
Daily AI digest
AI Retail Discussion Summary: StockTwits messages indicate a bullish sentiment towards $RPRX, with traders anticipating a potential surge in the stock price as iShares Biotechnology ETF (XBI) begins to perform similarly to Ascendis Pharma (ASND). No recent news articles were available for analysis.
Key Retail Themes: Anticipated price surge due to XBI performance Positive sentiment towards $RPRX
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams. View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 12:56 AM ET
Data refreshes hourly during market hours. Next update: 1:56 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
See Full Scanner Results »
Technical Signals Check

Is RPRX showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for RPRX.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
IONS
Ionis Pharmaceuticals Inc 		STRONG BUY
25 analysts 		$84 50 HOLD
ACLX
Arcellx Inc 		STRONG BUY
18 analysts 		$113 50 HOLD
JANX
Janux Therapeutics Inc 		STRONG BUY
18 analysts 		$32 51 HOLD
GPCR
Structure Therapeutics I… 		STRONG BUY
16 analysts 		$107 50 HOLD
ABVX
Abivax SA American Depos… 		STRONG BUY
12 analysts 		$164 63 BUY
IONS Ionis Pharmaceuti…
50 HOLD
ACLX Arcellx Inc
50 HOLD
JANX Janux Therapeutic…
51 HOLD
GPCR Structure Therape…
50 HOLD
ABVX Abivax SA America…
63 BUY

Advanced RPRX Option Strategies

Professional options setups generated by AI based on today's RPRX price and gamma walls.

Iron Condor Bull Call Bear Put Collar

Explore More Analysis & Live Quant Tools

Part A: Deep-Dive RPRX Research Pages
RPRX Technical Chart RPRX Price Prediction RPRX Intrinsic Value DCF RPRX Earnings Date RPRX Investment Advisor RPRX Fair Price Analyzer RPRX Options Chain RPRX Options Advisor RPRX Options Analysis RPRX Competitors
Part B: Tradestie Flagship Market Scanners
Today's Best Signals (RPRX) Sector Rotation Monitor AI Supply Chain Money Flow Gamma Squeeze (GEX) Scanner Undervalued Stocks Scanner Insider Cluster Buying Reddit & WSB Sentiment Tracker Backtested Stock Scanner
Compare RPRX with Peers
RPRX vs GTM
Which one to buy?
RPRX vs NCNO
Which one to buy?
RPRX vs CYTK
Which one to buy?
RPRX vs ALNY
Which one to buy?
RPRX vs GDRX
Which one to buy?
RFL vs RPRX
IONS vs RPRX
Winner: RPRX
RPRX vs REGN
RPRX vs SMMT
GNLX vs RPRX
CORT vs RPRX
FBRX vs RPRX
PRAX vs RPRX
Winner: RPRX
MRNA vs RPRX
COYA vs RPRX
Create New Comparison View All Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals